BioMimetic Therapeutics Inc Announces
Selected Abstract
BioMimetic Therapeutics, Inc. Announces Patent Allowance from United States Patent and Trademark Office for PDGF Compositions Patent.
Expanded protection for Augment[TM], Augment[TM] Injectable and GEM 21S([R]) until 2024 FRANKLIN, Tenn. -- BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the United States Patent Office has allowed the Company's U.S. patent application No. 11/159,533 titled Platelet-Derived Growth ... November 21, 2008; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
BioMimetic Therapeutics, Inc. Announces Pricing of Public Offering.
2.
BioMimetic Therapeutics, Inc. Announces Pricing of Initial Public Offering.
3.
BioMimetic Therapeutics, Inc. Announces Patent Allowance from United States Patent and Trademark Office for PDGF Compositions Patent.
|
